<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853252</url>
  </required_header>
  <id_info>
    <org_study_id>9366</org_study_id>
    <nct_id>NCT03853252</nct_id>
  </id_info>
  <brief_title>iPS Cells of Patients for Models of Retinal Dystrophies</brief_title>
  <acronym>RETIPS</acronym>
  <official_title>iPS Cells of Patients for Models of Retinal Dystrophies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are focused on inherited retinal dystrophies with an aim to further
      understand disease pathophysiology and to elaborate novel treatments, as, to date, there is
      no effective treatment to prevent blindness.

      The main goal of this study is to generate human cellular models of healthy and disease
      retinas and perform studies to evaluate the efficiency of gene therapy approaches for
      different diseases.

      Skin biopsies of volunteers are cultured to isolate fibroblasts that are then reprogrammed
      into iPS cells. Healthy and disease-specific iPS cells are then differentiated into retinal
      models.

      This study should help to elucidate disease pathways and to provide proof-of-concept for
      various therapeutic approaches.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2014</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of human cell models obtained</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Retinal Dystrophies</condition>
  <arm_group>
    <arm_group_label>Skin biopsy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)</description>
    <arm_group_label>Skin biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Signed informed consent and

          -  Choroideremia :

               -  Males

               -  CHM mutation

               -  With multimodal Imaging anomalies in line with CHM

          -  All other presumed inherited retinal dystrophies with bilateral and symmetrical
             involvement with identified mutations in one of the Retnet gene

          -  All presumed inherited optic neuropathy with bilateral and symmetrical involvement
             with identified mutations

          -  And in all cases or pattern

               -  Age from 5 to 70

               -  with appropriate health insurance

        Exclusion criteria :

          -  Patient under tutorship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vasiliki Kalatzis, PhD</last_name>
    <phone>(0)499636097</phone>
    <phone_ext>+33</phone_ext>
    <email>vasiliki.kalatzis@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CNMR Maolya, Genetic Sensory Diseases</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34294</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MEUNIER, PhD</last_name>
      <phone>(0)467330278</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelannemeunier@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

